Removing the NGS Analytics Data Bottleneck with Field-Programmable Gate Arrays (FPGA’s)

Edico Genome’s FPGA-backed DRAGEN Bio-IT Platform Now Available on DNAnexus

The following is a guest blog, written by our partners at Edico Genome.

With rapid adoption across a variety of practices, next-generation sequencing (NGS) is on track to become one of the largest producers of big data by 2025. While the integration of NGS poses exceptional breakthroughs in its applied practices, one major problem threatens its expansion: a lack of computing power to analyze the rapidly growing body of data.

Current projections calculate genomic data to continue doubling every seven months, a stark acceleration in comparison to Moore’s Law, which states CPU capabilities will double every two years. The void left in-between creates a bottleneck for genomics labs.

Designed to uncork this big data bottleneck, Edico Genome’s DRAGEN™ (Dynamic Read Analysis for Genomics) Platform leverages FPGA (Field-Programmable Gate Array) technology to provide customers with hardware-accelerated implementation of genome pipeline algorithms. Leveraging FPGAs, DRAGEN allows customers to analyze NGS data at unprecedented speeds with extremely high accuracy and unwavering dependability.

Uncorking the big data bottleneck with DRAGEN

In contrast to conventional CPU-based systems, which must execute lines of software code to perform an algorithmic function, FPGAs implement algorithms as logic circuits, providing an output almost instantaneously. By replicating these logic circuits thousands of times over, DRAGEN is able to achieve industry-leading speeds by allowing for massive parallelism, unlike CPUs, which are limited to running only one task per core. FPGAs are also fully reconfigurable, enabling customers to switch between functions and pipelines within seconds.

As a result, DRAGEN delivers high accuracy while functioning with industry-leading speed, efficiency, and parallelism. DRAGEN can process an entire human genome at 30x coverage in about 90 minutes, as compared to over 30 hours using a traditional CPU-based system, saving customers time and money. DRAGEN’s Genome Pipeline is now available on DNAnexus at a reduced trial rate until October 31, 2017. To sign up for exclusive promotional pricing, visit: .

DNAnexus and Saphetor Collaborate for Seamless Integration of Tertiary Analysis Solution

DNAnexus has teamed up with Saphetor, a leading variant analysis company, to build a sample-in, report-out genomic analysis solution. Saphetor annotates and classifies genetic variants from next-generation sequencing (NGS) data to help clinicians quickly and accurately diagnose disease to make faster, more precise treatment decisions. Saphetor’s technology is now available on the DNAnexus cloud-based platform.

Saphetor has built a powerful genome interpretation engine by integrating more than 30 public and licensed databases containing genotype, phenotype, variant, drug, and clinical trial information. Automated annotation ensures a comprehensive understanding of variant significance and implication for disease. Each variant is annotated with gene and functional position, protein functional impact, population allele frequencies, and pathogenicity prediction scores. Using the DNAnexus-Saphetor integration, researchers globally can conduct secure, whole-genome analysis leveraging Saphetor’s databases containing 33 billion variant annotation points.

Data from the DNAnexus Platform is exported to Saphetor via a secure API, enabling customers to take advantage of this comprehensive analysis solution. Saphetor’s powerful user interface allows customers to interactively browse and use powerful filters on the annotated and classified variant list in an intuitive fashion. Click on the image below to see a sample of the variant analysis interface.

Together with the scalability and high-performance computing power of the DNAnexus Platform, and Saphetor’s variant browsing tools, customers can quickly move from NGS data analysis to interpretation. Researchers can discover which variants have a functional impact on disease in the hopes of accelerating the implementation of precision medicine. We are excited about our collaboration with Saphetor to offer a secure and scalable environment to power an end-to-end analytical solution for genomic biomarker discovery and interpretation.

Interested in trying out Saphetor’s technology on DNAnexus? Get in touch with a member of our Science Team.

The New UI: Sleeker. Modern. Intuitive.

We are pleased to announce a design refresh of the DNAnexus web user interface! The new, modern interface incorporates visual enhancements that make the most common tasks and interactions intuitive and delightful, without changing the underlying functions that power your biomedical research. Explore some of the updates below, highlighted in yellow.

Project List

Your list of projects and files has a sleeker layout and more intuitive filtering system. Looking for your Bookmarks? The Bookmarks tab has been renamed to Saved Filters so you can quickly find and access the projects you’re looking for.

Project Page

Managing workflows has never been easier. The main actions are listed using clear, modernized icons to help you know exactly which steps to take next. Each file also has a context menu. Clicking on these three dots will help you accomplish actions such as view, copy, delete, and download one item at a time. You can still apply bulk action to all the files by clicking the icons at the top of the page.

App Library

The available apps are displayed in a simplified and visually appealing manner. The inputs and outputs of each tool are clearly shown, and finding the appropriate app for your analysis is now easier than ever. 

Billing Information

Your user settings have been reorganized to show your billing information in one distinct location. This will help you easily review your budget, spend, and remaining funds.

We hope these changes make using the DNAnexus web interface an intuitive and seamless experience. If you have any questions about the updates, let us know at